

FORM PTO-1449 (Modified)

Attorney Docket No.
16930-000811USSerial No.:
08/889,355LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

(Use several sheets if necessary)

Applicant: HEIDRUN ENGLER et al.

Filing Date: 7/8/97

Group: To be Assigned

Reference Designation

U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
<u>mm</u> AA	5,013,556	05/07/91	Woodle et al.	A61K	37/22	
<u>mm</u> AB	5,108,921	04/28/92	Low et al.	C12N	5/00	
<u>mm</u> AC	5,166,320	11/24/92	Wu et al.	C07K	3/00	
<u>mm</u> AD	5,213,804	05/25/93	Martin et al.	A61K	9/127	
<u>mm</u> AE	5,279,833	01/18/94	Rose	A61K	37/22	
<u>mm</u> AF	5,283,185	02/01/94	Epand et al.	C12N	15/64	
<u>mm</u> AG	5,334,761	08/02/94	Gebeyehu et al.	C07C	233/36	
<u>mm</u> AH	5,346,701	09/13/94	Heiber et al.	A61F	13/02	
<u>mm</u> AI	5,521,291	05/28/96	Curiel et al.	C07K	16/08	
<u>mm</u> AJ	5,542,935	08/06/96	Unger et al.	A61M	5/00	
<u>mm</u> AK	5,552,309	09/03/96	March	A01N	63/00	
<u>mm</u> AL	5,554,386	09/10/96	Groman et al.	A61K	47/26	
<u>mm</u> AM	5,578,475	11/26/96	Jessee	C12N	15/64	
<u>mm</u> AN	5,580,859	12/03/96	Felgner et al.	A01N	43/04	
<u>mm</u> AO	5,589,466	12/31/96	Felgner et al.	A61K	48/00	
<u>mm</u> AP	5,601,818	02/11/97	Freeman et al.	A61K	48/00	
<u>mm</u> AQ	5,631,236	05/20/97	Woo et al.	A61K	48/00	

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (Yes/no)
<u>mm</u> AR	WO 92/06180	04/16/92	WIPO	C12N	7/00	
<u>mm</u> AS	WO 93/14188	07/22/93	WIPO	C12N	5/00	
<u>mm</u> AT	WO 93/19768	10/14/93	WIPO	A61K	37/00	
<u>mm</u> AU	WO 93/20221	10/14/93	WIPO	C12N	15/86	
<u>mm</u> AV	WO 94/06922	03/31/94	WIPO	C12N	15/87	
<u>mm</u> AW	WO 94/06923	03/31/94	WIPO	C12N	15/87	
<u>mm</u> AX	WO 95/11981	05/04/95	WIPO	C12N	15/86	No
<u>mm</u> AY	WO 97/27599	07/31/97	WIPO	H01C	7/12	No

FORM PTO-1449 (Modified)

MAR 02 1998

Attorney Docket No.

16930-000811US

Serial No.:

08/889,355

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE

Applicant: HEIDRUN ENGLER et al.

STATEMENT

(Use several sheets if necessary)

Filing Date: 7/8/97

Group: To be Assigned

Reference Designation

U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
AA	5,013,556	05/07/91	Woodle et al.	A61K	37/22	
AB	5,108,921	04/28/92	Low et al.	C12N	5/00	
AC	5,166,320	11/24/92	Wu et al.	C07K	3/00	
AD	5,213,804	05/25/93	Martin et al.	A61K	87/127	
AE	5,279,833	01/18/94	Rose	A61K	37/22	
AF	5,283,185	02/01/94	Epand et al.	C12N	15/64	
AG	5,334,761	08/02/94	Gebeyehu et al.	C07C	233/36	
AH	5,346,701	09/13/94	Heiber et al.	A61F	13/02	
AI	5,521,291	05/28/96	Curiel et al.	C07K	16/08	
AJ	5,542,935	08/06/96	Unger et al.	A61M	5/00	
AK	5,552,309	09/03/96	March	A01N	63/00	
AL	5,554,386	09/10/96	Groman et al.	A61K	47/26	
AM	5,578,475	11/20/96	Jessee	C12N	15/64	
AN	5,580,859	12/03/96	Felgner et al.	A01N	43/04	
AO	5,589,466	12/31/96	Felgner et al.	A61K	48/00	
AP	5,601,818	02/11/97	Freeman et al.	A61K	48/00	
AQ	5,631,236	05/20/97	Woo et al.	A61K	48/00	

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (yes/no)
AR	WO 92/06180	04/16/92	WIPO	C12N	7/00	
AS	WO 93/14188	07/22/93	WIPO	C12N	5/00	
AT	WO 93/19768	10/14/93	WIPO	A61K	37/00	
AU	WO 93/20221	10/14/93	WIPO	C12N	15/86	
AV	WO 94/06922	03/31/94	WIPO	C12N	15/87	
AW	WO 94/06923	03/31/94	WIPO	C12N	15/87	
AX	WO 95/11984	05/04/95	WIPO	C12N	15/86	No
AY	WO 97/27599	07/31/97	WIPO	H01C	7/12	No

FORM PTO-1449 (Modified)		Attorney Docket No. 16930-000811US	Serial No.: 08/889,355
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: HEIDRUN ENGLER et al.	
		Filing Date: 7/8/97	Group: To be Assigned
OTHER ARTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
<u>mm</u> AZ	Abe, A. et al., "Transduction of a Drug-Sensitive Toxic Gene into Human Leukemia Cell Lines with a Novel Retroviral Vector," <u>P.S.E.B.M.</u> 203:354-359 (1993)		
<u>mm</u> BA	Arteaga, C.L. et al., "Tissue-targeted Antisense c-fos Retroviral Vector Inhibits Established Breast Cancer Xenografts in Nude Mice," <u>Cancer Research</u> 56:1098-1103 (1996)		
<u>mm</u> BB	Banerjee, A. et al., "Changes in Growth and Tumorigenicity following Reconstitution of Retinoblastoma Gene Function in Various Human Cancer Cell Types by Microcell Transfer of Chromosome 13," <u>Cancer Research</u> 52:6297-6304 (1992)		
<u>mm</u> BC	Bass, C. et al., "Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo," <u>Cancer Gene Ther.</u> 2(2):97-104 (1995)		
<u>mm</u> BD	Blixt, Y. et al., "Enhancement of intracellular uncoating of adenovirus in HeLa cells in the presence of benzyl alcohol as a membrane fluidizer," <u>Arch. Virol.</u> 129:265-277 (1993)		
<u>mm</u> BE	Boulikas, "Gene Therapy of Prostate Cancer: p53, Suicidal Genes, and Other Targets," <u>Anticancer Research</u> 17:1471-1506 (1997)		
<u>mm</u> BF	Brewster, S.F. et al., "Gene Therapy in Urological Oncology: Principles, Strategies and Potential," <u>Eur. Urol.</u> 25:177-182 (1994)		
<u>mm</u> BG	Cairns, P. et al., "Loss of heterozygosity at the RB locus is frequent & correlates with muscle invasion in bladder carcinoma," <u>Oncogene</u> 6:2305-2309 (1991)		
<u>mm</u> BH	Cooper, M.J. et al., "Safety-modified episomal vectors for human gene therapy," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 94:6450-6455 (1997)		
<u>mm</u> BI	Curiel, D.T. et al., "Adenovirus enhancement of transferrin-polylysine-mediated gene delivery," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 88:8850-8854 (1991)		
<u>mm</u> BJ	Dalesandro, J. et al., "Cardiac and Pulmonary Replacment," <u>J. Thoracic Cardio. Surg.</u> 111(2):416-422 (1996)		
<u>mm</u> BK	Fujimoto, K. et al., "Frequent Association of p53 Gene Mutation in Invasive Bladder Cancer," <u>Cancer Research</u> 52:1393-1398 (1992)		
<u>mm</u> BL	Ginsberg, H.S. et al., "Role of early region 3 (E3) in pathogenesis of adenovirus disease," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 86:3823-3827 (1989)		
<u>mm</u> BM	Good, N.E. et al., "Hydrogen Ion Buffers for Biological Research," <u>Biochemistry</u> 5(2):467-477 (1966)		
<u>mm</u> BN	Goodrich, D.W. et al., "Expression of the Retinoblastoma Gene Product in Bladder Carcinoma Cells Associates with a Low Frequency of Tumor Formation," <u>Cancer Research</u> 52:1968-1973 (1992)		
<u>mm</u> BO	Grenay, H. et al., "Characterization of Imidazoline Binding Protein(s) Solubilized from Human Brainstem: Studies with [³ H]Idazoxan and [³ H]Clonidine," <u>Neurochem. Int.</u> 25(2):183-191 (1994)		

FORM PTO-1449 (Modified)		Attorney Docket No. 16930-000811US	Serial No.: 08/889,355
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: HEIDRUN ENGLER et al.	
		Filing Date: 7/8/97	Group: To be Assigned
<u>mm</u> BP	Greenberg, R. et al., "Intravesical AD32 (N-Trifluoroacetyl Adriamycin-14-Valerate) in the Treatment of Patients with Refractory Bladder Carcinoma - Clinical Efficacy, Pharmacology, and Safety," <u>Proc. Am. Urol. Assoc.</u> 153 Supp 233A:19 (1995)		
<u>mm</u> BQ	Hemström, C. et al., "Gene Product of Region E4 of Adenovirus Type 5 Modulates Accumulation of Certain Viral Polypeptides," <u>J. Virol.</u> 62(9):3258-3264 (1988)		
<u>mm</u> BR	Huang, S. et al., "A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product," <u>Nature</u> 350:160-162 (1991)		
<u>mm</u> BS	Ji, W. et al., "Inhibition of hepatitis B virus by retroviral vectors expressing antisense RNA," <u>J. Viral Hep.</u> 4:167-173 (1997)		
<u>mm</u> BT	Kaneda, Y. et al., "Prevention of Restenosis by Gene Therapy," <u>Annals N.Y. Acad. Sci.</u> 811:299-310 (1997)		
<u>mm</u> BU	Koç, O.N. et al., "Transfer of Drug Resistance Genes Into Hematopoietic Progenitors to Improve Chemotherapy Tolerance," <u>Sem. Oncol.</u> 23(1):46-64 (1996)		
<u>mm</u> BV	Lee, R.J. et al., "Lipidic Vector Systems for Gene Transfer," <u>Crit. Rev. Ther. Drug Carrier Sys.</u> 14(2):173-206 (1997)		
<u>mm</u> BW	Li, Q. et al., "Assessment of Recombinant Adenoviral Vectors for Hepatic Gene Therapy," <u>Hum. Gene. Ther.</u> 4:403-409 (1993)		
<u>mm</u> BX	Makarov, S.S. et al., "Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 93:402-406 (1996)		
<u>mm</u> BY	Marshall, E., "Gene Therapy's Growing Pains," <u>Science</u> 269:1050-1055 (1995)		
<u>mm</u> BZ	Miller, N. et al., "Targeted vectors for gene therapy," <u>FASEB J.</u> 9:190-199 (1995)		
<u>mm</u> CA	Monson, F.C. et al., "Indigocarmine as a quantitative indicator of urothelial integrity," <u>J. Urol.</u> 145:842-845 (1991)		
<u>mm</u> CB	Morris, B.D. et al., "Adenoviral-mediated gene transfer to bladder in vivo," <u>J. Urol.</u> 152:506-509 (1994)		
<u>mm</u> CC	Murayama, Y. et al., "Antisense Oligonucleotides to p53 Tumor Suppressor Suppress the Induction of Apoptosis by Epidermal Growth Factor in NCI-H 596 Human Lung Cancer Cells," <u>Antisense Nucl. Acid Drug Devel.</u> 7:109-114 (1997)		
<u>mm</u> CD	Niidome, T. et al., "Binding of Cationic α -Helical Peptides to Plasmid DNA and Their Gene Transfer Abilities into Cells," <u>J. Biol. Chem.</u> 272(24):15307-15312 (1997)		
<u>mm</u> CE	Nolta, J.A. et al., "Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 93:2414-2419 (1996)		
<u>mm</u> CF	Parsons, C.L. et al., "Bladder surface glycosaminoglycans: an epithelial permeability barrier," <u>J. Urol.</u> 143:139-142 (1990)		

FORM PTO-1449 (Modified)		Attorney Docket No. 16930-000811US	Serial No.: 08/889,355
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: HEIDRUN ENGLER et al.	
		Filing Date: 7/8/97	Group: To be Assigned
<u>mu</u> CG	Pinnaduwege, P. et al., "Use of a quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells," <u>Biochim. Biophys. Acta</u> 985:33-37 (1989)		
<u>mu</u> CH	Plank, C. et al., "The Influence of Endosome-disruptive Peptides on Gene Transfer Using Synthetic Virus-like Gene Transfer Systems," <u>J. Biol. Chem.</u> 269(17):12918-12924 (1994)		
<u>mu</u> CI	Raper, S.E. et al., "Safety and Feasibility of Liver-Directed Ex Vivo Gene Therapy for Homozygous Familial Hypercholesterolemia," <u>Annals Surgery</u> 223(2):116-126 (1996)		
<u>mu</u> CJ	Rosenberg, S.A., "The Immunotherapy and Gene Therapy of Cancer," <u>J. Clin. Oncol.</u> 10(2):180-199 (1992)		
<u>mu</u> CK	Sandberg, J.W. et al., "Improving Access to Intestinal Stem Cells as a Step Toward Intestinal Gene Transfer," <u>Human Gene Therapy</u> 5:323-329 (1994)		
<u>mu</u> CL	Spandidos, D.A. et al., "Expression of the Normal H-ras1 Gene can Suppress the Transformed and Tumorigenic Phenotypes Induced by Mutant ras Genes," <u>Anticancer Research</u> 10:1543-1554 (1990)		
<u>mu</u> CM	Takahashi, R. et al., "The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 88:5257-5261 (1991)		
<u>mu</u> CN	Vidal, P. et al., "Nouvelle stratégie pour vectorisation d-ARN dan des cellules de mammifères. Utilisation d'un vecteur peptidique," <u>CR Acad. Sci III</u> 32:279-287 (1997)		
<u>mu</u> CO	Wills, K.N. et al., "Development and Characterization of Recombinant Adenoviruses Encoding Human p53 for Gene Therapy of Cancer," <u>Hum. Gene Ther.</u> 5:1079-1088 (1994)		
<u>mu</u> CP	Wills, K.N. et al., "Gene therapy for hepatocellular carcinoma: Chemosensitivity conferred by adenovirs-mediated transfer of the HSV-1 thymidine kinase gene," <u>Cancer Gene Ther.</u> 2(3):191-197 (1995)		
<u>mu</u> CQ	Wu, G.Y. et al., "Receptor-mediated Gene Delivery and Expression in Vivo," <u>J. Biol. Chem.</u> 263(29):14621-14624 (1988)		
<u>mu</u> CR	Xiao, X. et al., "Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA _A α_1 containing receptors and increases inferior collicular seizure sensitivity," <u>Brain Res.</u> 756:76-83 (1997)		
<u>mu</u> CS	Yew, N.S. et al., "Optimization of Plasmid Vectors for High-Level Expression in Lung Epithelial Cells," <u>Human Gene Therapy</u> 8:575-584 (1997)		
<u>mu</u> CT	Cancer Facts & Figures 1995, <u>Am. Canc. Soc.</u> 5-11 (1995)		
EXAMINER	DATE CONSIDERED <u>6-7-99</u>		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.